Marco Sardina

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11818031/publications.pdf

Version: 2024-02-01

840776 794594 1,260 21 11 19 citations h-index g-index papers 21 21 21 1253 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis. New England Journal of Medicine, 2005, 353, 2229-2242.	27.0	880
2	Effects of Safinamide on Pain in Fluctuating Parkinson's Disease Patients: A Post-Hoc Analysis. Journal of Parkinson's Disease, 2017, 7, 95-101.	2.8	72
3	Lung function in idiopathic pulmonary fibrosis - extended analyses of the IFIGENIA trial. Respiratory Research, 2009, 10, 101.	3.6	70
4	Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis. Journal of Parkinson's Disease, 2015, 5, 475-481.	2.8	62
5	Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia. Journal of Pharmacology and Experimental Therapeutics, 2018, 364, 198-206.	2.5	42
6	Disposition and Metabolism of Safinamide, a Novel Drug for Parkinson's Disease, in Healthy Male Volunteers. Pharmacology, 2013, 92, 207-216.	2.2	30
7	Pharmacokinetics of ITF 296 (Sinitrodil) a novel organic nitrate, in healthy volunteers. European Journal of Pharmaceutical Sciences, 1999, 7, 179-184.	4.0	14
8	Efficacy, tolerability and safety of a new medical device, Monurelle Biogel \hat{A}^{\otimes} vaginal gel, in the treatment of vaginal dryness: a randomized clinical trial in women of reproductive age. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2016, 203, 82-88.	1.1	14
9	Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease. Pharmacology Research and Perspectives, 2016, 4, e00251.	2.4	12
10	Three-Month Therapy with Calcium-Heparin in Comparison with Ticlopidine in Patients with Peripheral Arterial Occlusive Disease at Leriche-Fontaine IIb Class. Angiology, 1993, 44, 307-313.	1.8	11
11	Effects of iloprost, either administered for 1 week or 4 weeks, on systemic hemodynamics, peripheral blood flow, and exercise tolerance in patients with peripheral occlusive arterial disease at leriche-fontaine stage III. International Journal of Angiology, 1998, 7, 28-33. Randomized trial of the effects of low-cose calcium-heparin in patients with peripheral arterial	0.6	11
	disease and claudication 11 CAP Study Group: Enrico Feraco, MD, Orlando Grandinetti, MD (Cardiology) Tj ETQq	0 0 0 rgBT	/Overlock 10

Pedrinelli, MD, Elio Melillo, MD (1st Medical Clinic, University of Pisa), Gianfranco Boccoli, MD,

12

#	Article	IF	CITATIONS
19	Hemodynamic and Humoral Effects at Rest and After Head-Up Tilt Tests During 24-Hour Infusion of a New Nitrate Ester, ITF 296, Compared with ISDN and Placebo in Healthy Volunteers. Journal of Cardiovascular Pharmacology, 1995, 26, S80.	1.9	2
20	Verapamil 240 SR versus verapamil 120 SR in arterial hypertension. A randomized double-blind, placebo-controlled study with 24-hour ambulatory blood pressure monitoring. Cardiovascular Drugs and Therapy, 1990, 4, 1501-1507.	2.6	0
21	Safety, Tolerability, and Antiischaemic Efficacy of ITF-296, a Nitric Oxide Donor, in Patients with Chronic Stable Angina. Journal of Cardiovascular Pharmacology, 1998, 32, 295-299.	1.9	0